RPHM News

Just two IPOs priced this past week, raising $222 million as the US IPO market continued to cool down. They were joined by eight SPACs that raised $1.5 million. The IPO pipeline remained active, with 13 IPOs and 14 SPACs submitting initial filings this week. Swiss rare disease biotech VectivBio Holding (VECT) priced at the midpoint to raise $128 million at a...read more

Reneo Pharmaceuticals, a Phase 2 biotech developing therapies for rare genetic mitochondrial diseases, raised $94 million by offering 6.3 million shares at $15, the low end of the range of $15 to $17. At pricing, Reneo  commands a fully diluted market cap of $397 million. Reneo Pharmaceuticals plans to list on the Nasdaq under the symbol RPHM. Jefferies, SVB Leerink and...read more

Reneo Pharmaceuticals, a Phase 2 biotech developing therapies for rare genetic mitochondrial diseases, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Reneo Pharmaceuticals would command a fully diluted market value of $425...read more

The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. The week’s IPOs were joined by 24 SPACs that raised $8.4 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings. Chinese IoT platform developer Tuya (TUYA) priced above the range to raise $915 million at an $11.8 billion...read more